SCHEMBL2546800

SCHEMBL2546800

N#CCCCc1ccccc1Br

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.50
CYP1A1 P04798 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP1B1 Q16678 1/20 0.42
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
IDO1 P14902 2/20 0.39
NLRP3 Q96P20 1/20 0.38
MPO P05164 1/20 0.37
SLC6A4 P31645 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PYCR1 P32322 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
TSHR P16473 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31317862 0.88 TAAR1 (0.54) TAAR1CYP1A1CYP1A2CYP1B1IDO1
SCHEMBL1459814 0.88 TAAR1 (0.54) TAAR1CYP1A1CYP1A2CYP1B1IDO1
SCHEMBL25324795 0.80 ATM (0.40) TAAR1CYP1A1CYP1A2CYP1B1ATM
SCHEMBL8852219 0.76 ATM (0.41) CYP1A1CYP1A2CYP1B1ATML3MBTL1
SCHEMBL1151026 0.76 TAAR1 (0.50) TAAR1ATML3MBTL1MPOSLC6A4
SCHEMBL1150149 0.76 ATM (0.41) ATML3MBTL1MPOSLC6A4MEN1
SCHEMBL6999612 0.76 MPO (0.50) TAAR1ATML3MBTL1MPOSLC6A4
SCHEMBL6770101 0.76 ATM (0.41) CYP1A1CYP1A2CYP1B1ATML3MBTL1
SCHEMBL1150773 0.76 TAAR1 (0.50) TAAR1ATML3MBTL1IDO1SLC6A4
SCHEMBL8648514 0.76 ATM (0.45) CYP1A1CYP1A2CYP1B1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893575-B1 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES H LUNDBECK AS (DK) 2017-01-11 EP disclosed
EP-2190811-B1 RENIN INHIBITORS MERCK CANADA INC (CA) 2013-08-07 EP disclosed
US-8334308-B2 Renin inhibitors MERCK SHARP & DOHME CORP. (US) 2012-12-18 US disclosed
US-8334308-B2 Renin inhibitors MERCK SHARP & DOHME CORP. (US) 2012-12-18 US disclosed
US-8334308-B2 Renin inhibitors MERCK SHARP & DOHME CORP. (US) 2012-12-18 US disclosed
US-20110263658-A1 RENIN INHIBITORS MERCK CANADA INC. (CA) 2011-10-27 US disclosed
US-20110263658-A1 RENIN INHIBITORS MERCK CANADA INC. (CA) 2011-10-27 US disclosed
US-20110263658-A1 RENIN INHIBITORS MERCK CANADA INC. (CA) 2011-10-27 US disclosed
EP-2190811-A1 RENIN INHIBITORS Merck Frosst Canada Ltd. (CA) 2010-06-02 EP disclosed
US-7629473-B2 2-(1H-indolylsulfanyl)-aryl amine derivatives H. LUNDBECK A/S (DK) 2009-12-08 US disclosed
WO-2009023964-A1 RENIN INHIBITORS MERCK FROSST CANADA LTD. (CA) 2009-02-26 WO disclosed
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ALLERGAN, INC. 2008-10-16 US disclosed
CN-101238101-A 2-(1H-indolylsulfanyl)-aryl amine derivatives LUNDBECK & CO AS H (DK) 2008-08-06 CN disclosed
CN-101208324-A Benzo [ b ] furan and benzo [ b ] thiophene derivatives LUNDBECK & CO AS H (DK) 2008-06-25 CN disclosed
EP-1893596-A2 BENZOÝB¨FURANE AND BENZOÝB¨THIOPHENE DERIVATIVES H.Lundbeck A/S (DK) 2008-03-05 EP disclosed
EP-1893575-A2 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES H.Lundbeck A/S (DK) 2008-03-05 EP disclosed
WO-2007023395-A2 BENZO[B]FURANE AND BENZO[B]THIOPHENE DERIVATIVES H. LUNDBECK A/S (US) 2007-03-01 WO disclosed
WO-2006134499-A2 2-(1H-INDOLYLSULFANYL)-ARYL AMINE DERIVATIVES H. LUNDBECK A/S (DK) 2006-12-21 WO disclosed
US-20060287382-A1 2-(1H-indolylsulfanyl)-aryl amine derivatives H. LUNDBECK A/S (DK) 2006-12-21 US disclosed
US-20060287386-A1 Benzo[b]furane and benzo[b]thiophene derivatives H. LUNDBECK A/S (DK) 2006-12-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287386-A1 Benzo[b]furane and benzo[b]thiophene derivatives CYP1B1, TBCB, CYP4B1 TAAR1 1517/4885CYP1A1 145/4885CYP1A2 165/4885
US-20110263658-A1 RENIN INHIBITORS REN, ACE, AGTR1 TAAR1 2165/4885CYP1A1 476/4885CYP1A2 654/4885
US-20060287382-A1 2-(1H-indolylsulfanyl)-aryl amine derivatives CYP11B2, CYP1A2, CYP4B1 TAAR1 341/4885CYP1A1 38/4885CYP1A2 2/4885
US-20080255239-A1 SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS ADRB2, ADRA2A, ADRA2C TAAR1 1909/4885CYP1A1 1172/4885CYP1A2 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.